Mesoblast Limited (ASX: MSB)
Australia
· Delayed Price · Currency is AUD
2.420
-0.630 (-20.66%)
Dec 20, 2024, 4:10 PM AEST
Mesoblast Revenue
In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M USD, down -21.32%. Mesoblast had revenue of $1.26M in the quarter ending June 30, 2024, a decrease of -41.23%.
Revenue
$5.90M
Revenue Growth
-21.32%
P/S Ratio
269.96
Revenue / Employee
$80.85K
Employees
73
Market Cap
2.76B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 22.18B |
ResMed Inc. | 6.93B |
Pro Medicus Limited | 161.50M |
Fisher & Paykel Healthcare Corporation Limited | 1.74B |
Cochlear Limited | 2.24B |
Sonic Healthcare Limited | 8.97B |
Telix Pharmaceuticals Limited | 645.68M |
Ramsay Health Care Limited | 16.66B |
Mesoblast News
- 2 days ago - What's Going On With Mesoblast Shares Thursday? - Benzinga
- 2 days ago - Mesoblast Finally Gets Its Approval In GVHD: Where Now? - Seeking Alpha
- 2 days ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 2 days ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 2 days ago - Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
- 2 days ago - Mesoblast shares rocket on FDA approval, but CEO says risks remain - The Australian Financial Review
- 3 days ago - FDA Approves Mesoblast's RYONCIL as First MSC Therapy for Pediatric SR-aGvHD - GuruFocus
- 3 days ago - Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - GlobeNewsWire